Neuraxis Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuraxis Inc reports strong Q3 growth and eyes future opportunities

Neuraxis Inc's Q3 2024 earnings call highlighted robust financial performance, strategic milestones, and a positive outlook for future revenue growth and financial stability.
The company's focus on achieving cash flow breakeven, expanding insurance coverage, and leveraging key achievements positions it well for sustained success.
While challenges in market penetration and revenue expectations exist, Neuraxis has opportunities to drive growth through therapy efficacy, market expansion, and guideline publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.

NeurAxis Reports Third Quarter 2023 Financial Results

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of CareFirst Blue Cross Blue Shield (“CareFirst BCBS”) policy coverage for the mid-Atlantic region with 3.5 million lives. CareFirst BCBS is the largest healthcare insurer in the mid-Atlantic that includes Maryland, Washington DC, and Northern Virginia.

NeurAxis Announces CareFirst BCBS Policy Coverage

CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has secured a $3 million financing for NeurAxis through a preferred stock offering priced at $2.38 per share.

NeurAxis Secures $3 Million Financing

CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has executed an exclusive option agreement with the University of Michigan for the exclusive licensing of its innovative rectal expulsion device (RED). The RED redesigns the balloon expulsion testing workflow to directly simplify anorectal function testing downstream to any gastroenterologist's office.   During the option agreement period, NeurAxis intends to evaluate the vast market potential for RED.

NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the second quarter ended June 30, 2023.

NeurAxis Reports Second Quarter 2023 Financial Results

CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will present at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 9:00 am ET.

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the publication of Prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms, featured in the September 2023 Frontiers in Pain Research.

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS™) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms.

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.

NeurAxis Highlights Strength of its Board of Directors

CARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published independent studies showing that IB-Stim therapy leads to improvements in abdominal pain and disability in adolescents with IBS and that the gut microbiome may play an important role.

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. NeurAxis is conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced a poster presentation from the University of Michigan that highlighted the cost-effectiveness of its PENFS or IB-Stim™ therapy in the treatment of irritable bowel syndrome (IBS) in adolescents at the 2023 American Neurogastroenterology and Motility Society (ANMS) Annual Meeting in Austin, TX.

NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023

Adlai Nortye Ltd

Aurora Acquisition Corp

Black Spade Acquisition Co

Fitell Corp

LQR House Inc

Nature Wood Group Ltd

VinFast Auto Ltd

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

BALTIMORE, MD / ACCESSWIRE / August 11, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on NeurAxis, Inc. (NYSE American:NRXS). NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults.

Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.

CARMEL, Ind., Aug. 09, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the pricing of its underwritten initial public offering of 1,098,667 shares of common stock at an initial public offering price of $6.00 per share. The gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $6,592,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to 164,800 additional shares of common stock at the initial public offering price, less the underwriting discount.

NeurAxis Announces Pricing of Initial Public Offering

Earlyworks Co Ltd

Structure Therapeutics Inc

Inno Holdings Inc

Janover Inc

Keen Vision Acquisition Corp

ParaZero Technologies Ltd

Pixie Dust Technologies Inc

Surf Air Mobility Inc

Warrantee Inc

A handful of small IPOs and one direct listing closed out the last full week of July. Aviation company Surf Air Mobility completed the first direct listing of 2023, opening 75% below its reference price to begin trading at $5.

U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.

Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

Neuraxis, Inc. has filed proposed terms for a $15 million U.S. IPO. The firm is developing neuromodulation technologies for the treatment of various pediatric digestive and nausea conditions.

Neuraxis Seeks $15 Million IPO For Device Expansion

Neuraxis has filed to raise $33 million in a U.S. IPO, although the final figure may differ. The company is developing and commercializing neurostimulation treatments for irritable bowel syndrome and other health conditions.

Neuraxis Begins $33 Million U.S. IPO Effort

News for Neuraxis Inc Stock (NRXS)